IL7 and pancreatic neoplasm: In another study, the intravenous injection of interleukin 7 (IL-7) and Chemokine (C-C motif) ligand-19 (CCL19)-MSLN secreting CAR-T cells (NCT03198546) in a patient with advanced pancreatic cancer induced complete regression of the tumor 240 days post-treatment [72].